Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Rindopepimut · CDX-110

Vaccine (Peptide vaccine) · Immune activation, directed at EGFRvIII (EGFR) · developed by Celldex Therapeutics

Phase 2 Most advanced trial (none active)

CLDX Developer

1 Registered trials

What is Rindopepimut?

Rindopepimut (CDX-110) is a peptide vaccine made of an EGFRvIII-specific peptide conjugated to the immunomodulator keyhole limpet hemocyanin. It is designed to elicit a cytotoxic T-lymphocyte response against tumor cells expressing EGFRvIII, a variant of EGFR not expressed in normal tissues. It is studied in glioblastoma and related glioma conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CDX-110
Drug type: Vaccine (Peptide vaccine)
Targets: EGFRvIII (EGFR) (antigen)
Mechanism: Immune activation, directed at EGFRvIII (EGFR)
Therapy area: Oncology
Developer: Celldex Therapeutics (CLDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: K3L4X0501F

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01498328	Phase 2	Glioblastoma	Completed	CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Giant Cell GlioblastomaGlioblastomaGlioblastoma With Oligodendroglial ComponentGliosarcomaRecurrent GlioblastomaRelapsed GlioblastomaSmall Cell Glioblastoma

Other drugs acting on EGFR

Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 Firmonertinib Phase 3 FPI-2053 Phase 1 Izalontamab Brengitecan Phase 2/3

More from Celldex Therapeutics

Barzolvolimab Phase 3 CDX 0158 Phase 1 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-1307 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-585 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Keyhole Limpet Hemocyanin Phase 2

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind Rindopepimut

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z